Radiolabeled somatostatin analogs represent valuable tools for both in vivo diagnosis and
therapy of neuroendocrine tumors (NETs) because of the frequent tumoral overexpression of …

Somatostatin receptor PET tracers such as [68Ga-DOTA, 1-Nal3]-octreotide (68Ga-
DOTANOC) and [68Ga-DOTA, Tyr3]-octreotate (68Ga-DOTATATE) have shown promising …

Somatostatin receptor imaging is a valuable tool in the diagnosis, follow-up, and treatment
planning of neuroendocrine tumor (NET). PET-based tracers using 68Ga as the radioisotope …

BACKGROUND. The aim was to assess the relevant distribution of the novel PET tracer
68Ga‐DOTATATE in neuroendocrine tumors (NETs) with combined positron emission …

Purpose Recent studies have suggested that positron emission tomography (PET) imaging
with 68 Ga-labelled DOTA-somatostatin analogues (SST) like octreotide and octreotate is …

Neuroendocrine tumors have shown rising incidence mainly due to higher clinical
awareness and better diagnostic tools over the last 30 years. Functional imaging of …

The use of positron emitter–labeled compounds for somatostatin receptor imaging (SRI) has
become attractive because of the prospect of improved spatial resolution, accelerated …

Our purpose was to evaluate the safety and efficacy of 68Ga-DOTATATE PET/CT compared
with 111In-pentetreotide imaging for diagnosis, staging, and restaging of pulmonary and …

Studies demonstrate that the investigational 64Cu-DOTATATE radiopharmaceutical may
provide diagnostic and logistical benefits over available imaging agents for patients with …

111In-diethylenetriaminepentaacetic acid (DTPA)-octreotide scintigraphy is currently the
nuclear medicine imaging modality of choice for identifying neuroendocrine tumors …